Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

In 2017, the European Medicines Agency approved rituximab biosimilars (R-biosimilars) for treatment of diffuse large B-cell lymphoma (DLBCL). Thereafter, the Netherlands was one of the first countries to implement R-biosimilars, given lower costs compared with rituximab originator (R-originator). This study's objective was to investigate whether overall survival (OS) of patients with DLBCL receiving R-biosimilars is similar to patients treated with R-originator. DLBCL patients >18 years, diagnosed between 2014 and 2018, who received at least 1 cycle of rituximab combined with cyclophosphami... Mehr ...

Volltext
Verfasser: Brink, M.
Kahle, X.U.
Vermaat, J.S.P.
Zijlstra, J.M.
Chamuleau, M.
Kersten, M.J.
Durmaz, M.
Plattel, W.J.
Lugtenburg, P.J.
Stevens, W.
Mous, R.
de Vries, E.G.E.
van der Poel, M.W.M.
Panday, P.V.N.
Huls, G.
van Meerten, T.
Nijland, M.
Dokumenttyp: Artikel
Erscheinungsdatum: 2021
Reihe/Periodikum: Brink , M , Kahle , X U , Vermaat , J S P , Zijlstra , J M , Chamuleau , M , Kersten , M J , Durmaz , M , Plattel , W J , Lugtenburg , P J , Stevens , W , Mous , R , de Vries , E G E , van der Poel , M W M , Panday , P V N , Huls , G , van Meerten , T & Nijland , M 2021 , ' Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study ' , Blood advances , vol. 5 , no. 15 , pp. 2958-2964 . https://doi.org/10.1182/bloodadvances.2021004295
Schlagwörter: ELDERLY-PATIENTS / EFFICACY / SAFETY / CHOP
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29021229
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://cris.maastrichtuniversity.nl/en/publications/8a98fabe-be22-4b91-ac07-f45b60e74956